Table 3. Comparison of results from pivotal trials and other ‘real-world' data in eyes receiving 0.5 mg ranibizumab.

Regimen	PRN										24 Fixed monthly injections		Treat and extend
study	This study	CATTb	IVANc	PRONTO	Querques et al25	Michalova et al13	Rotsos et al12	Rothenbuehler et al8	Kang et al11	Cohen et al7	MARINA	ANCHOR	Gupta et al16
Number of patients receiving 0.5 mg ranibzumab	406	298	314	40	96	165	50	138	64	122	240a	140a	92
Mean baseline VA	54.4	61.5	61.8	56.2	46.0	62.7	46	49.7	33.3	56.2	59.6	57.1	43.7
Percentage of eyes that lost fewer than 15 ETDRS letters at 1 year	90.1	95.4	Not available	95	98.4	93.0	84.0	92	85.9	90.3	94.6	96.4	96
Percentage of eyes that gained 15 or more ETDRS letters at 1 year	20.9	34.2	Not available	35	15	26.0	26	31	Not available	8.0	33.8	40.3	32
Mean change in VA from baseline at 1 year	+4.1	+6.8	+7.2	+9.3	+9.0	+5.47	+4.6	+7.3	+7.9	+0.7	+7.2	+11.3	+12.0
Mean change in VA from end of loading phase to 1 year	0.0	+3.5	Not available	+1.5	Not available	Not available	Not available	Not available	Not available	Not available	+1.3	+1.3	+2.1
Mean VA (ETDRS letters) at 1 year	58.5	68.4	69.0	65.5	55.0	68.2	50.6	57.0	41.2	56.9	60.9	58.4	55.7
Mean number of injections	5.9	6.9	10.0	5.6	6.4	9.0	4.7	5.6	4.2	3.79	12	12	8.36
Mean number of follow-up visits	12.2	13	13	13	Not available	Not available	11	Not available	Not available	8.07	13	13	Not available

^aRanibizumab subgroup data.

^bRanibizumab as-needed group.

^cRanibizumab group (continuous and discontinuous).